{
    "nctId": "NCT03285568",
    "briefTitle": "Patterns of Prescribing and Monitoring of Palbociclib",
    "officialTitle": "Patterns of Prescribing and Monitoring of Palbociclib",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer, Advanced Breast Cancer, Estrogen Receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 67,
    "primaryOutcomeMeasure": "Palbociclib dose according to the package insert recommendations.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* women at least 18 years old\n* ER+, HER2- advanced breast cancer\n* receiving palbociclib\n\nExclusion Criteria:\n\n* brain metastases\n* on palbociclib clinical trial",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT"
}